Treatment of functional dyspepsia using asimadoline
OwnerMatthias Wiesner, Christoph Seyfriedinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with covalently bonded acids, and to the salts, solvates and prodrugs thereof, to the derivatives as medicaments, to the use of these derivatives for the preparation of a medicament, to the use of these derivatives for the preparation of a pharmaceutical composition, to a process for the preparation of the said pharmaceutical compositions, to pharmaceutical compositions obtainable by this process, and to a process for the treatment of diseases which comprises the administration of the said pharmaceutical composition.
Claims14
1-23. (canceled)
A method for treating functional dyspepsia in a human comprising administering an effective amount of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride to a human having functional dyspepsia.
A method for treating functional dyspepsia in a human comprising administering about 0.1 mg to about 10 mg daily of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride to a human having functional dyspepsia, wherein the treatment influences nausea and/or pain.
Dependencies are inferred from the claim text.